ERBB2 and metastatic malignant neoplasm in the lymph nodes: Firstly, these results confirm the prognostic value of HER2, as opposed to the Kumar et al. [7] study where HER2 overexpression was not correlated with staging, lymph node metastasis or recurrence of the disease.